RecruitingPhase 3NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
Boston, MA · +452 more sites
Leukemia clinical trials in Boston, MA
56 recruiting leukemia studies with a site in Boston, MA.
RecruitingPhase 2NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Sponsor: National Cancer Institute (NCI)
Boston, MA · Worcester, MA · +113 more sites
RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Boston, MA · Burlington, MA · +172 more sites
RecruitingPhase 2NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Boston, MA · +222 more sites
RecruitingPhase not listedNCT04028531
Understanding Chronic Lymphocytic Leukemia
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 2NCT06672146
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Boston, MA · +134 more sites
RecruitingPhase 1 / Phase 2NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Sponsor: Syndax Pharmaceuticals
Boston, MA · +21 more sites
RecruitingPhase 1NCT06440135
Ziftomenib Maintenance Post Allo-HCT
Sponsor: Massachusetts General Hospital
Boston, MA · +1 more sites
RecruitingPhase 2NCT07061951
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Sponsor: National Cancer Institute (NCI)
Boston, MA · +8 more sites
RecruitingPhase 2NCT06707493
Ivosidenib as Post-HSCT Maintenance for AML
Sponsor: Massachusetts General Hospital
Boston, MA · +5 more sites
RecruitingPhase 2NCT05592015
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Sponsor: Jonathan Brammer
Boston, MA · +2 more sites
RecruitingPhase 3NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor: BeOne Medicines
Boston, MA · +21 more sites
RecruitingPhase 1 / Phase 2NCT04925479
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Sponsor: Novartis Pharmaceuticals
Boston, MA · +7 more sites
RecruitingPhase 3NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Sponsor: Janssen Research & Development, LLC
Boston, MA · +57 more sites
RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Boston, MA · +183 more sites
RecruitingPhase 2NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Sponsor: Cogent Biosciences, Inc.
Boston, MA · +13 more sites
RecruitingPhase 1 / Phase 2NCT03471260
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Sponsor: M.D. Anderson Cancer Center
Boston, MA · +3 more sites
RecruitingPhase 1NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Sponsor: New York Medical College
Boston, MA · +15 more sites
RecruitingPhase 1 / Phase 2NCT03104491
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Sponsor: Leland Metheny
Boston, MA · +6 more sites
RecruitingPhase 1NCT05010005
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Boston, MA · +8 more sites
RecruitingNot applicableNCT06907797
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 1NCT03666000
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sponsor: Imugene Limited
Boston, MA · +9 more sites
RecruitingPhase 2 / Phase 3NCT03013998
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Sponsor: Beat AML, LLC
Boston, MA · +30 more sites
RecruitingPhase 1NCT07439211
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Sponsor: Jacqueline Garcia, MD
Boston, MA
RecruitingPhase 1 / Phase 2NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Sponsor: PedAL BCU, LLC
Boston, MA · +163 more sites
RecruitingPhase 1NCT06247787
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Sponsor: Children's Oncology Group
Boston, MA · +18 more sites
RecruitingPhase 1NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: Kura Oncology, Inc.
Boston, MA · +37 more sites
RecruitingPhase 2NCT07227584
ALL Backbone in AYAs
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingNot applicableNCT07671209
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Sponsor: Massachusetts General Hospital
Boston, MA
RecruitingPhase not listedNCT04968834
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
Sponsor: Dana-Farber Cancer Institute
Boston, MA · +6 more sites
RecruitingNot applicableNCT06469307
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase not listedNCT07675967
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 3NCT06104566
Global Trial in APG2575 for Patients With CLL/SLL
Sponsor: Ascentage Pharma Group Inc.
Boston, MA · +10 more sites
RecruitingPhase 1NCT03113643
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sponsor: Dana-Farber Cancer Institute
Boston, MA · +2 more sites
RecruitingPhase 1NCT04024761
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 1NCT06138587
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase not listedNCT05865301
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Sponsor: Stanford University
Boston, MA · +21 more sites
RecruitingPhase 1NCT03219450
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase not listedNCT05978141
A Registry for People With T-cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Boston, MA · +24 more sites
RecruitingPhase 2NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Loxo Oncology, Inc.
Boston, MA · +20 more sites
RecruitingPhase not listedNCT01790152
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Sponsor: Children's Oncology Group
Boston, MA · +68 more sites
RecruitingPhase not listedNCT02269592
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Sponsor: Dana-Farber Cancer Institute
Boston, MA · Brighton, MA · Methuen, MA · +4 more sites
RecruitingPhase 1NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Sponsor: Newave Pharmaceutical Inc
Boston, MA · +7 more sites
RecruitingPhase 1 / Phase 2NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sponsor: Sumitomo Pharma America, Inc.
Boston, MA · +31 more sites
RecruitingPhase 1NCT05292664
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Sponsor: Andrew E. Place, MD
Boston, MA · +4 more sites
RecruitingPhase 4NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Sponsor: Eli Lilly and Company
Boston, MA · +19 more sites
RecruitingPhase 1 / Phase 2NCT07148180
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Sponsor: Jacqueline Garcia, MD
Boston, MA
RecruitingPhase 2NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Sponsor: Inhye Ahn
Boston, MA · +1 more sites
RecruitingPhase 1 / Phase 2NCT07052695
Mosunetuzumab for CLL MRD Clearance
Sponsor: Inhye Ahn
Boston, MA
RecruitingNot applicableNCT06472128
Novel Digital Application for Patients With Acute Leukemia
Sponsor: Massachusetts General Hospital
Boston, MA · +2 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.